Showing results (151-160 of 193) with videos related to
Sort By:
Pageof 20
Anti-Cancer Drugs|February 2, 2023
The incidence and risk factors for acute kidney injury in patients treated with immune checkpoint inhibitorsDeniz Can Guven, Deniz Aral Ozbek, Taha Koray Sahin, et al.Cancer Biomarkers : Section a of Disease Markers|December 27, 2021
The association between albumin-globulin ratio (AGR) and survival in patients treated with immune checkpoint inhibitorsDeniz Can Guven, Oktay Halit Aktepe, Melek Seren Aksun, et al.Cancer Medicine|December 23, 2023
The efficacy of immunotherapy and chemoimmunotherapy in patients with advanced rare tumors: A Turkish oncology group (TOG) studyDeniz Can Guven, Musa Baris Aykan, Harun Muglu, et al.BMJ Supportive & Palliative Care|October 29, 2021
Newly diagnosed cancer and the COVID-19 pandemic: tumour stage migration and higher early mortalityDeniz Can Guven, Taha Koray Sahin, Hasan Cagri Yildirim, et al.Journal of Clinical Medicine|February 27, 2026
Efficacy, Safety, and Survival Outcomes of Immune Checkpoint Inhibitors in Patients with Mismatch Repair-Deficient Colorectal Cancer: A Retrospective, Multicenter StudyMehmet Cihan İcli, Deniz Can Guven, Arif Akyildiz, et al.Future Oncology (London, England)|February 8, 2024
Efficacy and safety of bevacizumab in patients with low-grade serous ovarian cancerCengiz Karacin, Veli Sunar, Zuhat Urakci, et al.Current Oncology (Toronto, Ont.)|October 27, 2023
Evaluation of Anti-Mullerian Hormone Levels, Antral Follicle Counts, and Mean Ovarian Volumes in Chemotherapy-Induced Amenorrhea among Breast Cancer Patients: A Prospective Clinical StudyÇağlar Ünal, Çetin Ordu, Tolga Özmen, et al.Medicine|July 26, 2024
The impact of human epidermal growth factor receptor-2 (low) status on the efficacy of first line cyclin-dependent kinase 4/6 inhibitors in advanced breast cancerHasan Cagri Yildirim, Mustafa Buyukkor, Gözde Kavgaci, et al.Experimental Hematology & Oncology|June 9, 2026
Statins enhance trastuzumab deruxtecan efficacy: preclinical synergy in HER2-negative models and clinical benefit in HER2-positive metastatic breast cancerTaha Koray Sahin, Cemal Orhan, Ibrahim Hanifi Ozercan, et al.Breast (Edinburgh, Scotland)|October 8, 2022
Clinical outcomes of cyclin-dependent kinase 4-6 (CDK 4-6) inhibitors in patients with male breast cancer: A multicenter studyHasan Çağrı Yıldırım, Emel Mutlu, Elvin Chalabiyev, et al.Pageof 20